NRXPW — NRx Pharmaceuticals Inc

NRx Pharmaceuticals Inc (NRXPW) common stock listed on NASDAQ. It is led by Jonathan C. Javitt M.D., M.P.H., based in 1201 N. Market Street, Wilmington, DE, United States, 19801, with about 29 employees. NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.

Latest reported NRXPW revenue for 2025-09-30 was $242.0K. Net income was -$5.9M. NRXPW currently screens at market cap $714.6M.

Use this NRXPW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NRXPW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NRXPW SEC filings page. Lician reads the product cache first so this HTML stays unique to NRx Pharmaceuticals Inc even when a live quote feed is slow.